
USFDANov 13, 2026, 06:16 AM
GSK's Bexsero Booster for Meningitis B Receives Positive CHMP Opinion
AI Summary
GSK plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended updating the Bexsero label. The update would include a single booster dose for individuals aged 10 years and older who were previously vaccinated with Bexsero at least two years earlier. This recommendation is based on data from a Phase IIIb study showing that immune memory established in infancy can be boosted up to 19 years later, potentially helping to maintain protection into adolescence when disease incidence peaks again. If approved, this single-dose booster could help reduce the overall burden of Invasive Meningococcal Disease (IMD).
Key Highlights
- GSK's Bexsero (4CMenB) receives positive CHMP opinion for a single-dose Meningitis B booster.
- The booster is for individuals aged 10 years and older, previously vaccinated at least two years prior.
- Data shows immune memory from infancy vaccination can be boosted up to 19 years later.
- The booster aims to maintain protection into adolescence, a period of increased disease risk.
- Phase IIIb study Men-B-096 supported the positive opinion, meeting its primary endpoint.
- Bexsero is registered in 61 countries for preventing Meningococcal Disease serogroup B.
Price Impact
More from GSK